Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer

B. S. Adiwijaya, J. Kim, I. Lang, T. Csõszi, A. Cubillo, J. S. Chen, M. Wong, J. O. Park, J. S. Kim, K. M. Rau, B. Melichar, J. B. Gallego, J. Fitzgerald, B. Belanger, I. Molnar, Wen Wee Ma

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Nanoliposomal irinotecan (nal-IRI) is a liposomal formulation of irinotecan with a longer half-life (t1/2), higher plasma total irinotecan (tIRI), and lower SN-38 maximum concentration (Cmax) compared with nonliposomal irinotecan. Population pharmacokinetic (PK) analysis of nal-IRI was performed for tIRI and total SN-38 (tSN38) using patient samples from six studies. PK-safety association was evaluated for neutropenia and diarrhea in 353 patients. PK-efficacy association was evaluated from a phase III study in pancreatic cancer NAPOLI1. Efficacy was associated with longer duration of unencapsulated SN-38 (uSN38) above a threshold and higher Cavg of tIRI, tSN38, and uSN38. Neutropenia was associated with uSN38 Cmax and diarrhea with tIRI Cmax. Baseline predictive factors were race, body surface area, and bilirubin. Analysis identified PK factors associated with efficacy, safety, and predictive baseline factors. The results support the benefit of nal-IRI dose of 70 mg/m2 (free-base; equivalent to 80 mg/m2 salt base) Q2W over 100 mg/m2 Q3W.

Original languageEnglish (US)
Pages (from-to)997-1005
Number of pages9
JournalClinical Pharmacology and Therapeutics
Volume102
Issue number6
DOIs
StatePublished - Dec 1 2017

Fingerprint

irinotecan
Pharmacokinetics
Population
Neoplasms
Neutropenia

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer. / Adiwijaya, B. S.; Kim, J.; Lang, I.; Csõszi, T.; Cubillo, A.; Chen, J. S.; Wong, M.; Park, J. O.; Kim, J. S.; Rau, K. M.; Melichar, B.; Gallego, J. B.; Fitzgerald, J.; Belanger, B.; Molnar, I.; Ma, Wen Wee.

In: Clinical Pharmacology and Therapeutics, Vol. 102, No. 6, 01.12.2017, p. 997-1005.

Research output: Contribution to journalArticle

Adiwijaya, BS, Kim, J, Lang, I, Csõszi, T, Cubillo, A, Chen, JS, Wong, M, Park, JO, Kim, JS, Rau, KM, Melichar, B, Gallego, JB, Fitzgerald, J, Belanger, B, Molnar, I & Ma, WW 2017, 'Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer', Clinical Pharmacology and Therapeutics, vol. 102, no. 6, pp. 997-1005. https://doi.org/10.1002/cpt.720
Adiwijaya BS, Kim J, Lang I, Csõszi T, Cubillo A, Chen JS et al. Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer. Clinical Pharmacology and Therapeutics. 2017 Dec 1;102(6):997-1005. https://doi.org/10.1002/cpt.720
Adiwijaya, B. S. ; Kim, J. ; Lang, I. ; Csõszi, T. ; Cubillo, A. ; Chen, J. S. ; Wong, M. ; Park, J. O. ; Kim, J. S. ; Rau, K. M. ; Melichar, B. ; Gallego, J. B. ; Fitzgerald, J. ; Belanger, B. ; Molnar, I. ; Ma, Wen Wee. / Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer. In: Clinical Pharmacology and Therapeutics. 2017 ; Vol. 102, No. 6. pp. 997-1005.
@article{27b064b9fd1b4f12bdd39ee2f136df61,
title = "Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer",
abstract = "Nanoliposomal irinotecan (nal-IRI) is a liposomal formulation of irinotecan with a longer half-life (t1/2), higher plasma total irinotecan (tIRI), and lower SN-38 maximum concentration (Cmax) compared with nonliposomal irinotecan. Population pharmacokinetic (PK) analysis of nal-IRI was performed for tIRI and total SN-38 (tSN38) using patient samples from six studies. PK-safety association was evaluated for neutropenia and diarrhea in 353 patients. PK-efficacy association was evaluated from a phase III study in pancreatic cancer NAPOLI1. Efficacy was associated with longer duration of unencapsulated SN-38 (uSN38) above a threshold and higher Cavg of tIRI, tSN38, and uSN38. Neutropenia was associated with uSN38 Cmax and diarrhea with tIRI Cmax. Baseline predictive factors were race, body surface area, and bilirubin. Analysis identified PK factors associated with efficacy, safety, and predictive baseline factors. The results support the benefit of nal-IRI dose of 70 mg/m2 (free-base; equivalent to 80 mg/m2 salt base) Q2W over 100 mg/m2 Q3W.",
author = "Adiwijaya, {B. S.} and J. Kim and I. Lang and T. Cs{\~o}szi and A. Cubillo and Chen, {J. S.} and M. Wong and Park, {J. O.} and Kim, {J. S.} and Rau, {K. M.} and B. Melichar and Gallego, {J. B.} and J. Fitzgerald and B. Belanger and I. Molnar and Ma, {Wen Wee}",
year = "2017",
month = "12",
day = "1",
doi = "10.1002/cpt.720",
language = "English (US)",
volume = "102",
pages = "997--1005",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer

AU - Adiwijaya, B. S.

AU - Kim, J.

AU - Lang, I.

AU - Csõszi, T.

AU - Cubillo, A.

AU - Chen, J. S.

AU - Wong, M.

AU - Park, J. O.

AU - Kim, J. S.

AU - Rau, K. M.

AU - Melichar, B.

AU - Gallego, J. B.

AU - Fitzgerald, J.

AU - Belanger, B.

AU - Molnar, I.

AU - Ma, Wen Wee

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Nanoliposomal irinotecan (nal-IRI) is a liposomal formulation of irinotecan with a longer half-life (t1/2), higher plasma total irinotecan (tIRI), and lower SN-38 maximum concentration (Cmax) compared with nonliposomal irinotecan. Population pharmacokinetic (PK) analysis of nal-IRI was performed for tIRI and total SN-38 (tSN38) using patient samples from six studies. PK-safety association was evaluated for neutropenia and diarrhea in 353 patients. PK-efficacy association was evaluated from a phase III study in pancreatic cancer NAPOLI1. Efficacy was associated with longer duration of unencapsulated SN-38 (uSN38) above a threshold and higher Cavg of tIRI, tSN38, and uSN38. Neutropenia was associated with uSN38 Cmax and diarrhea with tIRI Cmax. Baseline predictive factors were race, body surface area, and bilirubin. Analysis identified PK factors associated with efficacy, safety, and predictive baseline factors. The results support the benefit of nal-IRI dose of 70 mg/m2 (free-base; equivalent to 80 mg/m2 salt base) Q2W over 100 mg/m2 Q3W.

AB - Nanoliposomal irinotecan (nal-IRI) is a liposomal formulation of irinotecan with a longer half-life (t1/2), higher plasma total irinotecan (tIRI), and lower SN-38 maximum concentration (Cmax) compared with nonliposomal irinotecan. Population pharmacokinetic (PK) analysis of nal-IRI was performed for tIRI and total SN-38 (tSN38) using patient samples from six studies. PK-safety association was evaluated for neutropenia and diarrhea in 353 patients. PK-efficacy association was evaluated from a phase III study in pancreatic cancer NAPOLI1. Efficacy was associated with longer duration of unencapsulated SN-38 (uSN38) above a threshold and higher Cavg of tIRI, tSN38, and uSN38. Neutropenia was associated with uSN38 Cmax and diarrhea with tIRI Cmax. Baseline predictive factors were race, body surface area, and bilirubin. Analysis identified PK factors associated with efficacy, safety, and predictive baseline factors. The results support the benefit of nal-IRI dose of 70 mg/m2 (free-base; equivalent to 80 mg/m2 salt base) Q2W over 100 mg/m2 Q3W.

UR - http://www.scopus.com/inward/record.url?scp=85033396683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033396683&partnerID=8YFLogxK

U2 - 10.1002/cpt.720

DO - 10.1002/cpt.720

M3 - Article

C2 - 28445610

AN - SCOPUS:85033396683

VL - 102

SP - 997

EP - 1005

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -